Search results
Results From The WOW.Com Content Network
Tamsulosin was first marketed in 1996 under the trade name Flomax. The U.S. patent expired in October 2009. [26] The U.S. Food and Drug Administration (FDA) approved generics in March 2010. [27] In 2010, tamsulosin was available as OTC medication in UK. [28] It is marketed by various companies under licence, including Boehringer Ingelheim and CSL.
It is a combination of two previously existing medications: dutasteride, brand name Avodart, and tamsulosin, brand name Flomax. It contains 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride .
1966 – Taxol, anti-cancer compound, isolated from the yew plant; 1967 – Camptothecin, anti-cancer compound, isolated from the Camptotheca acuminata, the Chinese Happy Tree, which was used as a cancer treatment in traditional Chinese medicine. [23] It is the source of chemotherapy drugs: topotecan and irinotecan.
Intraoperative floppy iris syndrome (IFIS) is a complication that may occur during cataract extraction in certain patients. This syndrome is characterized by a flaccid iris which billows in response to ordinary intraocular fluid currents, a propensity for this floppy iris to prolapse towards the area of cataract extraction during surgery, and progressive intraoperative pupil constriction ...
This is because the brain has an extensive system in place to protect it from harmful chemicals. Drug transporters can pump out drugs from the brain and brain's blood vessel cells into the cerebrospinal fluid and blood circulation. These transporters pump out most chemotherapy drugs, which reduces their efficacy for treatment of brain tumors.
A 2010 review found a 25% reduction in the risk of prostate cancer with 5α-reductase inhibitor. [33] A follow-up study of the Medicare claims of participants in a 10-year Prostate Cancer Prevention Trial suggests the reduction in prostate cancer is maintained even after discontinuation of treatment. [34]
AOL latest headlines, entertainment, sports, articles for business, health and world news.
Exemestane is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to it for completion of a total of five consecutive years of adjuvant hormonal therapy. [3] US FDA approval was in October 1999. [4]